文献速递白血病

抗程序性死亡1抗体增强针对核磷蛋白1突变急性髓系白血病的抗原特异性免疫应答

Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody.
PubMed 文献 · Br J Haematol · 2022-07-07

研究探讨抗PD-1抗体纳武利尤单抗对NPM1突变型与野生型AML患者T细胞抗白血病干/祖细胞免疫应答的影响,发现纳武利尤单抗可增强白血病相关抗原刺激的细胞毒性T淋巴细胞及对LPC/LSC的杀伤,且对NPM1突变表位刺激的应答最强,提示NPM1突变AML或可从抗PD-1联合NPM1突变特异性免疫治疗中获益。

要点

  • 纳武利尤单抗增强LAA刺激的细胞毒性T淋巴细胞及对LPC/LSC的杀伤效应
  • 当免疫原性表位源自NPM1突变区时,对NPM1突变细胞的效应最强
  • 加用抗PD-1可进一步增强上述效应

核心结论

  • 数据提示NPM1突变AML患者或可接受免疫检查点抑制剂抗PD-1治疗,联合NPM1突变特异性免疫治疗对该独特患者群体可能更有效。

研究设计与样本

  • 研究检测AML患者针对NPM1及PRAME、Wilms瘤1、RHAMM三种白血病相关抗原的特异性免疫应答,采用集落形成免疫测定和流式细胞术评估针对白血病干/祖细胞的T细胞应答,并比较NPM1突变型与野生型AML患者细胞在抗PD-1抗体作用下的应答变化。

主要发现

  • 抗PD-1抗体纳武利尤单抗增加LAA刺激的细胞毒性T淋巴细胞及对LPC/LSC的细胞毒效应。
  • 当免疫原性表位源自NPM1突变区时,对NPM1突变细胞的效应最强,且加用抗PD-1后这些效应增强。

临床怎么用

  • 作者认为NPM1突变AML患者或可接受免疫检查点抑制剂抗PD-1治疗,联合NPM1突变特异性免疫治疗可能更有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nucleophosmin1 (NPM1) is one of the most commonly mutated genes in AML and is often associated with a favourable prognosis. Immune responses play an increasing role in AML treatment decisions; however, the role of immune checkpoint inhibition is still not clear. To address this, we investigated specific immune responses against NPM1, and three other leukaemia-associated antigens (LAA), PRAME, Wilms' tumour 1 and RHAMM in AML patients. We investigated T cell responses against leukaemic progenitor/stem cells (LPC/LSC) using colony-forming immunoassays and flow cytometry. We examined whether immune checkpoint inhibition with the anti-programmed death 1 antibody increases the immune response against stem cell-like cells, comparing cells from NPM1 mutated and NPM1 wild-type AML patients. We found that the anti-PD-1 antibody, nivolumab, increases LAA stimulated cytotoxic T lymphocytes and the cytotoxic effect against LPC/LSC. The effect was strongest against NPM1mut cells when the immunogenic epitope was derived from the mutated region of NPM1 and these effects were enhanced through the addition of anti-PD-1. The data suggest that patients with NPM1 mutated AML could be treated with the immune checkpoint inhibitor anti-PD-1 and that this treatment combined with NPM1-mutation specific directed immunotherapy could be even more effective for this unique group of patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Greiner J, Goetz M, Schuler PJ, et al. Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody. Br J Haematol. 2022. PMID: 35799423. doi:10.1111/bjh.18326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。